Retzinger, Gregory

Retzinger, Gregory was paid $12.99M by Medicaid between Jan 2018 and Dec 2024, across 259 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 9.1% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	369,006	$1.55M
2019	469,367	$1.89M
2020	472,014	$1.77M
2021	470,276	$1.77M
2022	486,291	$1.87M
2023	557,754	$2.09M
2024incomplete	531,287	$2.04M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
80053	Comprehensive metabolic panel	9.1%	242,206	116,465	$1.18M
80048	Basic metabolic panel (calcium, ionized)	7.0%	225,460	84,623	$905K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	6.6%	292,897	152,895	$858K
83735		6.0%	206,286	47,112	$776K
85027		4.0%	176,555	60,501	$516K
84443	Thyroid stimulating hormone (TSH)	2.9%	59,413	49,395	$372K
84100		2.3%	135,341	26,123	$298K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	2.2%	33,329	29,516	$285K
84484		1.7%	51,805	33,784	$216K
85610		1.5%	93,752	32,475	$197K
87086	Culture, bacterial; quantitative colony count, urine	1.5%	37,793	32,073	$193K
87040		1.5%	18,969	10,393	$189K

247 more codes

87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.5%	28,939	$189K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.4%	28,821	$188K
86780		1.3%	26,679	$173K
82607		1.3%	29,063	$172K
83880		1.2%	25,576	$158K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.1%	26,458	$144K
86850		1.1%	46,773	$139K
83036	Hemoglobin; glycosylated (A1C)	1.0%	41,601	$135K
80061	Lipid panel	<1%	37,745	$128K
82728		<1%	32,564	$128K
85730		<1%	38,160	$126K
80197		<1%	24,096	$125K
83615		<1%	51,042	$122K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	6,607	$117K
86901		<1%	51,023	$117K
82248		<1%	77,080	$116K
83690		<1%	33,538	$112K
81001		<1%	74,619	$107K
87340		<1%	18,188	$107K
82746		<1%	18,665	$105K
86803		<1%	16,981	$105K
84466		<1%	23,712	$102K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	15,353	$100K
82784		<1%	7,253	$87K
86900		<1%	50,993	$87K
83540		<1%	26,830	$84K
87081		<1%	27,852	$83K
86235		<1%	3,731	$83K
87186		<1%	14,434	$78K
84703		<1%	21,977	$78K
85379		<1%	19,304	$75K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	6,134	$74K
87205		<1%	38,474	$72K
84439		<1%	16,139	$70K
85520		<1%	19,746	$68K
86140		<1%	27,983	$65K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	10,953	$64K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	10,607	$63K
82570		<1%	25,802	$62K
86160		<1%	6,759	$62K
85384		<1%	19,309	$62K
87497		<1%	9,029	$61K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	9,662	$61K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	10,060	$60K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	3,681	$60K
84550		<1%	32,439	$60K
80069		<1%	13,927	$58K
87070		<1%	16,102	$55K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	7,599	$52K
86706		<1%	8,487	$50K
86147		<1%	4,201	$50K
87220		<1%	21,325	$50K
83883		<1%	3,043	$50K
86480		<1%	7,164	$48K
86704		<1%	7,907	$47K
84702		<1%	10,081	$45K
87075		<1%	7,077	$43K
87641		<1%	6,201	$39K
86038		<1%	6,536	$39K
83970		<1%	6,069	$38K
82550		<1%	12,785	$36K
86225		<1%	5,942	$34K
86787		<1%	5,621	$34K
80076		<1%	9,829	$33K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	6,118	$33K
80202		<1%	5,232	$31K
80180		<1%	4,896	$30K
82105		<1%	4,541	$27K
87493		<1%	4,121	$27K
89051		<1%	7,374	$26K
86762		<1%	6,019	$26K
82140		<1%	6,100	$26K
87116		<1%	3,763	$25K
87581		<1%	4,135	$25K
87486		<1%	4,132	$25K
86359		<1%	4,730	$25K
86360		<1%	4,257	$24K
86765		<1%	5,853	$24K
87536		<1%	3,521	$24K
84153		<1%	4,183	$24K
82150		<1%	6,722	$24K
82533		<1%	3,566	$23K
87799		<1%	2,766	$23K
87210		<1%	8,433	$21K
84403		<1%	3,480	$21K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	4,293	$21K
83001		<1%	3,251	$21K
85652		<1%	15,636	$20K
84156		<1%	17,822	$20K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	3,361	$20K
87088		<1%	3,713	$20K
86039		<1%	3,778	$20K
87529		<1%	2,190	$19K
87631		<1%	1,788	$19K
82670		<1%	3,332	$19K
83010		<1%	4,295	$19K
82247		<1%	9,678	$18K
84146		<1%	2,995	$18K
87102		<1%	5,256	$18K
86880		<1%	5,450	$18K
87522	Neg quan hep c or qual rna	<1%	2,501	$17K
85014		<1%	15,841	$17K
85018		<1%	15,849	$17K
87899		<1%	2,188	$17K
87184		<1%	4,144	$17K
84300		<1%	7,265	$16K
87045		<1%	2,659	$15K
82232		<1%	3,377	$15K
82043		<1%	7,514	$15K
82378		<1%	2,485	$15K
84481		<1%	2,938	$15K
83002		<1%	2,723	$15K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	2,240	$13K
87206		<1%	5,842	$13K
84480		<1%	2,903	$13K
83550		<1%	4,969	$13K
85045		<1%	9,740	$12K
87305		<1%	2,040	$12K
80164		<1%	2,636	$12K
84145		<1%	6,424	$12K
84478		<1%	5,718	$12K
86256		<1%	2,127	$12K
83930		<1%	4,532	$12K
86146		<1%	695	$11K
87015		<1%	2,866	$11K
80074		<1%	1,720	$11K
86790		<1%	1,830	$11K
82950		<1%	4,313	$11K
87481		<1%	1,156	$10K
86665		<1%	931	$10K
82330		<1%	1,244	$10K
86200		<1%	1,792	$10K
87632		<1%	1,285	$9K
82077		<1%	1,551	$9K
83935		<1%	3,839	$9K
86304		<1%	1,503	$9K
86644		<1%	1,496	$9K
82951		<1%	1,399	$9K
86431		<1%	2,452	$9K
83521		<1%	740	$8K
86870		<1%	1,216	$8K
86922		<1%	1,070	$8K
87077		<1%	6,855	$8K
87177		<1%	2,029	$7K
86800		<1%	1,225	$7K
87181		<1%	1,771	$7K
84540		<1%	3,859	$7K
87328		<1%	1,146	$7K
87517		<1%	978	$7K
86645		<1%	1,072	$6K
87541		<1%	1,354	$6K
82947		<1%	3,700	$6K
87046		<1%	2,695	$6K
86920		<1%	1,463	$6K
82010		<1%	2,043	$6K
87329		<1%	1,141	$6K
82553		<1%	1,225	$5K
85651		<1%	2,228	$5K
86592		<1%	2,432	$5K
86921		<1%	629	$5K
85007		<1%	2,659	$4K
82040		<1%	2,374	$4K
86355		<1%	707	$4K
82565		<1%	2,271	$4K
84157		<1%	3,251	$4K
86769		<1%	601	$4K
82945		<1%	2,522	$4K
86695		<1%	567	$4K
85613		<1%	912	$4K
82977		<1%	1,587	$4K
86696		<1%	526	$4K
86677		<1%	586	$3K
86376		<1%	722	$3K
86709		<1%	988	$3K
84144		<1%	553	$3K
85049		<1%	2,399	$3K
86255		<1%	694	$3K
82952		<1%	1,243	$2K
82042		<1%	952	$2K
86334		<1%	345	$2K
86705		<1%	379	$2K
84133		<1%	957	$2K
82627		<1%	348	$2K
81003		<1%	1,613	$2K
87281		<1%	332	$2K
82610		<1%	331	$2K
83516		<1%	336	$2K
84154		<1%	324	$2K
80195		<1%	401	$2K
86141		<1%	263	$2K
86735		<1%	273	$2K
82436		<1%	653	$2K
84432		<1%	253	$2K
84134		<1%	419	$1K
82310		<1%	998	$1K
86593		<1%	668	$1K
86357		<1%	204	$1K
84132		<1%	759	$1K
83090		<1%	207	$1K
86664		<1%	199	$1K
84155		<1%	807	$1K
82960		<1%	387	$1K
80158		<1%	181	$1K
86316		<1%	171	$1K
85670		<1%	403	$934.01
86308		<1%	328	$800.98
84165		<1%	297	$777.66
84295		<1%	399	$750.11
84460		<1%	459	$733.63
85576		<1%	135	$702.00
86777		<1%	115	$665.69
80050	General health panel	<1%	156	$594.00
86663		<1%	99	$588.00
80178		<1%	163	$546.11
86618		<1%	43	$510.00
81050		<1%	408	$509.32
86965		<1%	110	$505.00
80179		<1%	83	$504.00
80143		<1%	84	$504.00
82397		<1%	78	$468.00
84450		<1%	269	$400.15
83986		<1%	141	$344.96
86036		<1%	31	$324.00
84075		<1%	224	$306.37
86923		<1%	5,131	$265.52
83520		<1%	46	$258.68
81002		<1%	256	$176.06
80185		<1%	28	$168.85
86403		<1%	45	$154.78
80162		<1%	20	$120.00
84520		<1%	93	$113.29
85220		<1%	16	$96.00
81025		<1%	71	$88.86
84166		<1%	32	$87.24
82465		<1%	42	$84.92
86335		<1%	16	$73.80
80051		<1%	21	$72.03
86021		<1%	15	$46.50
84436		<1%	27	$39.96
87150		<1%	194	$39.80
89055		<1%	25	$37.25
87106		<1%	47	$36.30
80320		<1%	607	$30.47
86905		<1%	13	$29.64
85461		<1%	12	$18.96
G0476	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test	0%	78	$0.00
80329		0%	699	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.